Kinnov Therapeutics (KT) meets a new important milestone in galenic. To overcome the difficult observance of alcoholic patients, KT has developed and patented an innovative galenic form allowing a single daily intake of KT-110. This major challenge to deliver two active molecules with different PK and pharmacological profiles, has been met allowing application to ANSM* for evaluation of the new galenic on patients. The dossier has been accepted in March triggering the assays on the new formula on 8 patients. Results are expected for June 2024.

*ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) is the French Drug Regulatory Authority.